Jennifer E. Miller

TL;DR: The enactment of FDAAA was followed by significantly higher proportions of trials that were registered and reporting results on ClinicalTrials.gov and significantly lower degrees of publication bias among trials supporting recent FDA approval of drugs for neuropsychiatric indications.

TL;DR: In this article, the authors conducted a cross-sectional study examining the authorization or approval and delivery for COVID-19 vaccines recommended by the World Health Organization (WHO) in the countries where they were tested.

TL;DR: Because of the importance placed on AOAmembership, racial/ethnic membership imbalances could represent a form of structural racism and have profound implications for students, patients, medical research, and the diversity of the healthcare workforce.

TL;DR: In this article, a cross-sectional analysis of trials supporting FDA approval of novel drugs in 2012 and 2014, sponsored by large drug companies, did not involve human participants, and the settings were the countries hosting trials supporting US drug approval.

TL;DR: In this paper, the authors compared the reporting of demographic data and the representation of individuals by sex, age, and race in premarketing and post-marketing studies used by the Food and Drug Administration (FDA) to evaluate novel cancer therapeutics.